pharma · Colorectal Cancer Screening · Screening for Colon Cancer · MRKR
ME Therapeutics
Marker Therapeutics
ME Therapeutics is a pharma organization headquartered in Vancouver, CA. It trades on NYSE under ticker MRKR. Primary therapeutic focus areas include Colorectal Cancer Screening, Screening for Colon Cancer, Platinum Sens
Vancouver, British Columbia, CA HQ
2018 Founded
4 Employees
Public company Type
MRKR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Vancouver, British Columbia, CA
- Founded
- 2018
- Employees
- 4
- Programs
- 13
- Drugs
- 10
- Patents
- 27
HER-2/neu peptide vaccine
Phase 1 · mab · HER2-positive Breast Cancer
HER-2/neu peptide vaccine for HER2-positive Breast Cancer is a Phase 1 program (mab) at Marker Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code MC1136
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Marker Therapeutics
- Phase
- Phase 1
- Modality
- mab
- Indication
- HER2-positive Breast Cancer
- Status
- completed
- Trials
- 1